Core Viewpoint - Quantum BioPharma Ltd. is actively participating in two upcoming conferences to engage with institutional investors and showcase its innovative biopharmaceutical solutions [1][2]. Company Overview - Quantum BioPharma is a biopharmaceutical company focused on developing innovative assets and biotech solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders [4]. - The company is advancing its lead compound, Lucid-MS, which is designed to prevent and reverse myelin degradation associated with multiple sclerosis, currently in preclinical development [4]. - Quantum BioPharma retains a 22.95% ownership stake in Celly Nutrition Corp., which markets the unbuzzd™ product, and is entitled to a 7% royalty on sales until total payments reach $250 million, after which the royalty rate will decrease to 3% [4]. Conference Participation - Jason Sawyer, the Head of Finance and M&A, will represent Quantum BioPharma at the Sidoti Micro-Cap Conference on May 21, 2025, and the A.G.P. Virtual Healthcare Conference on May 22, 2025 [2][3]. - At the Sidoti Micro-Cap Conference, Sawyer will host one-on-one meetings with institutional investors and deliver a webcast presentation [2][3].
Quantum BioPharma to Attend Sidoti Micro-Cap Investor Conference and the AGP Virtual Healthcare Conference